Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have become significant global health concerns. In the present study, we aimed to investigate the effects of saroglitazar, a dual PPARα/γ agonist, fenofibrate, a PPAR-α agonist, and pioglitazone, a PPAR-γ...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbari, Rasoul, Behdarvand, Tahereh, Afarin, Reza, Yaghooti, Hamid, Jalali, Mohammad Taha, Mohammadtaghvaei, Narges
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485507/
https://www.ncbi.nlm.nih.gov/pubmed/34593018
http://dx.doi.org/10.1186/s40360-021-00524-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485507/
https://www.ncbi.nlm.nih.gov/pubmed/34593018
http://dx.doi.org/10.1186/s40360-021-00524-8

Ejemplares similares